CD38 and infection: Similarly, in the frail subgroup of the ALCYONE trial, higher rates ≥ grade 3 neutropenia (41.3% Dara-VMP vs. 34.4% VMP) and infection (30.0% Dara-VMP vs. 17.9% VMP) were observed with the addition of the anti-CD38 antibody [32].